Advanced search
Publication Cover
Clinical Ophthalmology Volume 15, 2021 - Issue
Submit an article Journal homepage
98
Views
1
CrossRef citations to date
0
Altmetric
Original Research

Baseline Subfoveal Choroidal Thickness as a Predictor for Response to Short-Term Intravitreal Bevacizumab Injections in Diabetic Macular Edema

Alaa Dweikat1 Department of Medicine, Faculty of Medicine and Health Sciences, An-Najah National University, Nablus, PalestineORCID Iconhttps://orcid.org/0000-0002-9729-7108
ORCID Icon,
Arkan Jarrar1 Department of Medicine, Faculty of Medicine and Health Sciences, An-Najah National University, Nablus, Palestine
,
Mohammad Akkawi2 Department of Special Surgeries, Faculty of Medicine and Health Sciences, An-Najah National University Hospital, An-Najah National University, Nablus, Palestine;3 Ophthalmology Department, An-Najah National University Hospital, Nablus, PalestineCorrespondence[email protected] [email protected]
,
Mohammad Shehadeh2 Department of Special Surgeries, Faculty of Medicine and Health Sciences, An-Najah National University Hospital, An-Najah National University, Nablus, Palestine;3 Ophthalmology Department, An-Najah National University Hospital, Nablus, Palestine
,
Ammar Aghbar3 Ophthalmology Department, An-Najah National University Hospital, Nablus, Palestine
,
Jamal Qaddumi1 Department of Medicine, Faculty of Medicine and Health Sciences, An-Najah National University, Nablus, Palestine
&
Maha Akkawi1 Department of Medicine, Faculty of Medicine and Health Sciences, An-Najah National University, Nablus, Palestine
 show all
Pages 4175-4180 | Published online: 18 Oct 2021

References

  • Romero-Aroca P. Managing diabetic macular edema: the leading cause of diabetes blindness. World J Diabetes. 2011;2(6):98–104. doi:10.4239/wjd.v2.i6.98
  • Yau JWY, Rogers SL, Kawasaki R, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012;35(3):556–564. doi:10.2337/dc11-1909
  • Das A, McGuire PG, Rangasamy S. Diabetic macular edema: pathophysiology and novel therapeutic targets. Ophthalmology. 2015;122(7):1375–1394. doi:10.1016/j.ophtha.2015.03.024
  • Kim JT, Lee DH, Joe SG, Kim JG, Yoon YH. Changes in choroidal thickness in relation to the severity of retinopathy and macular edema in type 2 diabetic patients. Invest Ophthalmol Vis Sci. 2013;54(5):3378–3384. doi:10.1167/iovs.12-11503
  • Adhi M, Brewer E, Waheed NK, Duker JS. Analysis of morphological features and vascular layers of choroid in diabetic retinopathy using spectral-domain optical coherence tomography. JAMA Ophthalmol. 2013;131(10):1267–1274. doi:10.1001/jamaophthalmol.2013.4321
  • Esmaeelpour M, Povazay B, Hermann B, et al. Mapping choroidal and retinal thickness variation in type 2 diabetes using three-dimensional 1060-nm optical coherence tomography. Invest Ophthalmol Vis Sci. 2011;52(8):5311–5316. doi:10.1167/iovs.10-6875
  • Miller AR, Roisman L, Zhang Q, et al. Comparison between spectral-domain and swept-source optical coherence tomography angiographic imaging of choroidal neovascularization. Invest Ophthalmol Vis Sci. 2017;58(3):1499–1505. doi:10.1167/iovs.16-20969
  • Kishi S. Impact of swept source optical coherence tomography on ophthalmology. Taiwan J Ophthalmol. 2016;6(2):58–68. doi:10.1016/j.tjo.2015.09.002
  • Musat O, Cernat C, Labib M, et al. Diabetic macular edema. Rom J Ophthalmol. 2015;59(3):133–136.
  • Schulze-Bonsel K, Feltgen N, Burau H, Hansen L, Bach M. Visual acuities “hand motion” and “counting fingers” can be quantified with the Freiburg visual acuity test. Invest Ophthalmol Vis Sci. 2006;47(3):1236–1240. doi:10.1167/iovs.05-0981
  • Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema. Early treatment diabetic retinopathy study report number 1. Arch Ophthalmol. 1985;103(12):1796–1806. doi:10.1001/archopht.1985.01050120030015
  • Do DV, Nguyen QD, Boyer D, et al. One-year outcomes of the da Vinci Study of VEGF trap-eye in eyes with diabetic macular edema. Ophthalmology. 2012;119(8):1658–1665. doi:10.1016/j.ophtha.2012.02.010
  • Solaiman KA, Diab MM, Dabour SA. Repeated intravitreal bevacizumab injection with and without macular grid photocoagulation for treatment of diffuse diabetic macular edema. Retina. 2013;33(8):1623–1629. doi:10.1097/IAE.0b013e318285c99d
  • Linsenmeier RA, Padnick-Silver L. Metabolic dependence of photoreceptors on the choroid in the normal and detached retina. Invest Ophthalmol Vis Sci. 2000;41(10):3117–3123.
  • Rayess N, Rahimy E, Ying GS, et al. Baseline choroidal thickness as a predictor for response to anti-vascular endothelial growth factor therapy in diabetic macular edema. Am J Ophthalmol. 2015;159(1):85–91 e81–e83. doi:10.1016/j.ajo.2014.09.033
  • Nourinia R, Ahmadieh H, Nekoei E, Malekifar P, Tofighi Z. Changes in central choroidal thickness after treatment of diabetic macular edema with intravitreal bevacizumab correlation with central macular thickness and best-corrected visual acuity. Retina. 2018;38(5):970–975. doi:10.1097/IAE.0000000000001645
  • Ross EL, Hutton DW, Stein JD, et al. Cost-effectiveness of Aflibercept, Bevacizumab, and Ranibizumab for diabetic macular edema treatment: analysis from the diabetic retinopathy clinical research network comparative effectiveness trial. JAMA Ophthalmol. 2016;134(8):888–896. doi:10.1001/jamaophthalmol.2016.1669

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.